GWPH News and Press, GW Pharmaceuticals Plc From 08/09/20

Despite the growing popularity of cannabis, there's limited information about what the substance can and cannot do. And with marijuana classified as a Schedule 1 substance in the U.S., it's nearly impossible for researchers to conduct studies on it. In Canada, however, pot's legal for both medic...

While smaller drugmakers such as GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals (NASDAQ: CRBP) have plowed headlong into medical marijuana research, most of the largest pharmaceutical companies have stayed on the sidelines. Most -- but not all. A few of the top names in the...

Investors were not happy with the Q2 fiscal 2020 results published by GW Pharmaceuticals (NASDAQ: GWPH) , a company that develops and markets cannabidiol (CBD)-based drugs and is therefore considered a marijuana stock. Those results, published after market close on Thursday, brought up...

This past week in the cannabis space, investors saw the return of a former publicly traded Canadian producer that experienced a fall from grace. Below the border, the US market provided plenty of updates — one longstanding executive left the troubles at her company, and the biggest ca...

Delta, Kelowna, BC - August 7, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from...

GW Pharmaceuticals plc. (GWPH) Q2 2020 Results Earnings Conference Call August 06, 2020, 04:30 PM ET Company Participants Stephen Schultz - VP, IR Justin Gover - CEO & Executive Director Darren Cline - U.S. Chief Commercial Officer Christopher Tovey - COO Volker Knappertz...

Shares of GW Pharmaceuticals   (NASDAQ: GWPH) are down 9.4% at 5:56 p.m. EDT on Thursday after the drugmaker released second-quarter results that didn't live up to expectations. On the surface, the sales jump for Epidiolex, which treats childhood epilepsy syndromes, looks great. Who's go...

GW Pharmaceuticals (NASDAQ: GWPH ) Q2 results : More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

GW Pharmaceuticals (NASDAQ: GWPH ) : Q2 GAAP EPS of -$0.02 beats by $0.02 . Revenue of $121.3M (+68.4% Y/Y) misses by $2.76M . Total Epidiolex net product sales of $117.7M. Press Release More news on: GW Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news, ...

- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - - Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceutic...